Cell News and Research

RSS

Findings highlight possible new approach to combat malaria

An international team of scientists, including researchers at Columbia University Medical Center, has identified a key metabolic enzyme that common malaria parasites require for survival at each stage of infection in humans. The findings raise the possibility of a new approach to combating malaria, one of the world's deadliest diseases. The study was published today in the online edition of the journal Nature.

27 Nov 2013

Health benefits of eating almonds

As Americans sit down to enjoy Thanksgiving dinner, they often wish their family and friends good health and a long life. Good news! With nuts like almonds on the table, these sentiments are more than just a traditional toast.

27 Nov 2013

DFG approves establishment of new Collaborative Research Centres

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has approved the establishment of nine new Collaborative Research Centres (CRCs).

27 Nov 2013

Study uncovers mechanisms that allow stem cells to keep dividing in perpetuity

The blood stem cells that live in bone marrow are at the top of a complex family tree. Such stem cells split and divide down various pathways that ultimately produce red cells, white cells and platelets. These "daughter" cells must be produced at a rate of about one million per second to constantly replenish the body's blood supply.

27 Nov 2013

Bioaxial secures funds to market optical microscopy modules

Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.

27 Nov 2013

Fluxion Biosciences reports first study results from early stage NSCLC patients

Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

From Fluxion Biosciences 27 Nov 2013

Edison initiates coverage of biotechnology company focused on adult stem therapies

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of Mesoblast (MSB: ASX), an Australian-headquartered biotechnology company focused on adult stem therapies.

27 Nov 2013

Research: Motor proteins transport mRNA to get where it is needed, prevent diseases

Scientists have found that mRNA may travel one way down a cell, then board another, aptly named motor protein, and head in the opposite direction to get where it ultimately needs to be.

27 Nov 2013

EPCs: A promising therapy for type 1 diabetes

Pancreatic islet transplantation is a promising therapy for treating type 1 diabetes, but the majority of transplanted cells die soon after they are transplanted.

27 Nov 2013

Inhibition of complement system plays major role in xenograft rejection

Researchers at the Bellvitge Institute of Biomedical Research (IDIBELL) led by Cristina Costa from the New Therapies on Genes and Transplantation group have shown that inhibition of one of the basic components of the complement system protects chondrocytes (cartilage cells) from porcine rejection of xenotransplantation (transplantation between animals of different species).

27 Nov 2013

Study shows most corneal transplants have remarkable longevity regardless of donor age

Ten years after a transplant, a cornea from a 71-year-old donor is likely to remain as healthy as a cornea from a donor half that age, and corneas from donors over 71 perform slightly less well but still remain healthy for most transplant recipients, according to a study funded by the National Eye Institute (NEI) and led by the UC Davis Health System Eye Center and the University of Cincinnati Eye Institut

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Protecting or boosting neurotrophins may slow progression of Huntington's disease

A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.

27 Nov 2013

Treatments based on behavioral or non-invasive physiological stimulation show greatest potential

Because the concept of permanent neurological injury has given way to recognition of the brain's potential for long-term regeneration ad reorganization, rehabilitations strategies are undergoing radical changes. The potential for five new translational interventions was examined in an article published ahead of print on November 13 by Neurology Clinical Practice: Barrett AM, Oh-Park M, Chen P, Ifejika NL: Five New Things in Neurorehabilitation.

27 Nov 2013

Thermo Fisher Scientific gets European Commission approval for Life Technologies deal

Thermo Fisher Scientific, the world leader in serving science, today announced that it has received approval from the European Commission for its pending acquisition of Life Technologies Corporation.

27 Nov 2013

Breakthrough discovery could lead to development of future therapeutics for prostate cancer

Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Survivors of hematopoietic stem cell transplant benefit from expressive helping

A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

27 Nov 2013

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.

27 Nov 2013

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Inhibitor compounds developed by UC Irvine structural biologists and Northwestern University chemists have been shown to bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.

27 Nov 2013

Cell News and Research

Findings highlight possible new approach to combat malaria

Health benefits of eating almonds

DFG approves establishment of new Collaborative Research Centres

Study uncovers mechanisms that allow stem cells to keep dividing in perpetuity

Bioaxial secures funds to market optical microscopy modules

Fluxion Biosciences reports first study results from early stage NSCLC patients

Edison initiates coverage of biotechnology company focused on adult stem therapies

Research: Motor proteins transport mRNA to get where it is needed, prevent diseases

EPCs: A promising therapy for type 1 diabetes

Inhibition of complement system plays major role in xenograft rejection

Study shows most corneal transplants have remarkable longevity regardless of donor age

UMass Medical School licenses "anti-gal" technology to Agalimmune

Protecting or boosting neurotrophins may slow progression of Huntington's disease

Treatments based on behavioral or non-invasive physiological stimulation show greatest potential

Thermo Fisher Scientific gets European Commission approval for Life Technologies deal

Breakthrough discovery could lead to development of future therapeutics for prostate cancer

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Survivors of hematopoietic stem cell transplant benefit from expressive helping

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

What are the challenges of cell line development? eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News